Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

Jennifer M. Giltnane, Katherine E. Hutchinson, Thomas P. Stricker, Luigi Formisano, Christian D. Young, Monica V. Estrada, Mellissa J. Nixon, Liping Du, Violeta Sanchez, Paula Gonzalez Ericsson, Maria G. Kuba, Melinda E. Sanders, Xinmeng J. Mu, Eliezer M. Van Allen, Nikhil Wagle, Ingrid A. Mayer, Vandana Abramson, Henry Gómez, Monica Rizzo, Weiyi ToySarat Chandarlapaty, Erica L. Mayer, Jason Christiansen, Danielle Murphy, Kerry Fitzgerald, Kai Wang, Jeffrey S. Ross, Vincent A. Miller, Phillip J. Stephens, Roman Yelensky, Levi Garraway, Yu Shyr, Ingrid Meszoely, Justin M. Balko, Carlos L. Arteaga

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Inhibition of proliferation in estrogen receptor-positive (ER+) breast cancers after short-term antiestrogen therapy correlates with long-term patient outcome. We profiled 155 ER+/human epidermal growth factor receptor 2-negative (HER2) early breast cancers from 143 patients treated with the aromatase inhibitor letrozole for 10 to 21 days before surgery. Twenty-one percent of tumors remained highly proliferative, suggesting that these tumors harbor alterations associated with intrinsic endocrine therapy resistance. Whole-exome sequencing revealed a correlation between 8p11-12 and 11q13 gene amplifications, including FGFR1 and CCND1, respectively, and high Ki67. We corroborated these findings in a separate cohort of serial pretreatment, postneoadjuvant chemotherapy, and recurrent ER+ tumors. Combined inhibition of FGFR1 and CDK4/6 reversed antiestrogen resistance in ER+ FGFR1/CCND1 coamplified CAMA1 breast cancer cells. RNA sequencing of letrozole-treated tumors revealed the existence of intrachromosomal ESR1 fusion transcripts and increased expression of gene signatures indicative of enhanced E2F-mediated transcription and cell cycle processes in cancers with high Ki67. These data suggest that short-term preoperative estrogen deprivation followed by genomic profiling can be used to identify druggable alterations that may cause intrinsic endocrine therapy resistance.

Original languageEnglish (US)
Article numberaai7993
JournalScience Translational Medicine
Volume9
Issue number402
DOIs
StatePublished - Aug 9 2017

Fingerprint

letrozole
Estrogens
Breast Neoplasms
Estrogen Receptor Modulators
Neoplasms
Exome
RNA Sequence Analysis
Aromatase Inhibitors
Gene Amplification
Ambulatory Surgical Procedures
Transcriptome
Estrogen Receptors
Cell Cycle
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. / Giltnane, Jennifer M.; Hutchinson, Katherine E.; Stricker, Thomas P.; Formisano, Luigi; Young, Christian D.; Estrada, Monica V.; Nixon, Mellissa J.; Du, Liping; Sanchez, Violeta; Ericsson, Paula Gonzalez; Kuba, Maria G.; Sanders, Melinda E.; Mu, Xinmeng J.; Van Allen, Eliezer M.; Wagle, Nikhil; Mayer, Ingrid A.; Abramson, Vandana; Gómez, Henry; Rizzo, Monica; Toy, Weiyi; Chandarlapaty, Sarat; Mayer, Erica L.; Christiansen, Jason; Murphy, Danielle; Fitzgerald, Kerry; Wang, Kai; Ross, Jeffrey S.; Miller, Vincent A.; Stephens, Phillip J.; Yelensky, Roman; Garraway, Levi; Shyr, Yu; Meszoely, Ingrid; Balko, Justin M.; Arteaga, Carlos L.

In: Science Translational Medicine, Vol. 9, No. 402, aai7993, 09.08.2017.

Research output: Contribution to journalArticle

Giltnane, JM, Hutchinson, KE, Stricker, TP, Formisano, L, Young, CD, Estrada, MV, Nixon, MJ, Du, L, Sanchez, V, Ericsson, PG, Kuba, MG, Sanders, ME, Mu, XJ, Van Allen, EM, Wagle, N, Mayer, IA, Abramson, V, Gómez, H, Rizzo, M, Toy, W, Chandarlapaty, S, Mayer, EL, Christiansen, J, Murphy, D, Fitzgerald, K, Wang, K, Ross, JS, Miller, VA, Stephens, PJ, Yelensky, R, Garraway, L, Shyr, Y, Meszoely, I, Balko, JM & Arteaga, CL 2017, 'Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance', Science Translational Medicine, vol. 9, no. 402, aai7993. https://doi.org/10.1126/scitranslmed.aai7993
Giltnane, Jennifer M. ; Hutchinson, Katherine E. ; Stricker, Thomas P. ; Formisano, Luigi ; Young, Christian D. ; Estrada, Monica V. ; Nixon, Mellissa J. ; Du, Liping ; Sanchez, Violeta ; Ericsson, Paula Gonzalez ; Kuba, Maria G. ; Sanders, Melinda E. ; Mu, Xinmeng J. ; Van Allen, Eliezer M. ; Wagle, Nikhil ; Mayer, Ingrid A. ; Abramson, Vandana ; Gómez, Henry ; Rizzo, Monica ; Toy, Weiyi ; Chandarlapaty, Sarat ; Mayer, Erica L. ; Christiansen, Jason ; Murphy, Danielle ; Fitzgerald, Kerry ; Wang, Kai ; Ross, Jeffrey S. ; Miller, Vincent A. ; Stephens, Phillip J. ; Yelensky, Roman ; Garraway, Levi ; Shyr, Yu ; Meszoely, Ingrid ; Balko, Justin M. ; Arteaga, Carlos L. / Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. In: Science Translational Medicine. 2017 ; Vol. 9, No. 402.
@article{96cb71ec668c449083bc3ecdf812168a,
title = "Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance",
abstract = "Inhibition of proliferation in estrogen receptor-positive (ER+) breast cancers after short-term antiestrogen therapy correlates with long-term patient outcome. We profiled 155 ER+/human epidermal growth factor receptor 2-negative (HER2) early breast cancers from 143 patients treated with the aromatase inhibitor letrozole for 10 to 21 days before surgery. Twenty-one percent of tumors remained highly proliferative, suggesting that these tumors harbor alterations associated with intrinsic endocrine therapy resistance. Whole-exome sequencing revealed a correlation between 8p11-12 and 11q13 gene amplifications, including FGFR1 and CCND1, respectively, and high Ki67. We corroborated these findings in a separate cohort of serial pretreatment, postneoadjuvant chemotherapy, and recurrent ER+ tumors. Combined inhibition of FGFR1 and CDK4/6 reversed antiestrogen resistance in ER+ FGFR1/CCND1 coamplified CAMA1 breast cancer cells. RNA sequencing of letrozole-treated tumors revealed the existence of intrachromosomal ESR1 fusion transcripts and increased expression of gene signatures indicative of enhanced E2F-mediated transcription and cell cycle processes in cancers with high Ki67. These data suggest that short-term preoperative estrogen deprivation followed by genomic profiling can be used to identify druggable alterations that may cause intrinsic endocrine therapy resistance.",
author = "Giltnane, {Jennifer M.} and Hutchinson, {Katherine E.} and Stricker, {Thomas P.} and Luigi Formisano and Young, {Christian D.} and Estrada, {Monica V.} and Nixon, {Mellissa J.} and Liping Du and Violeta Sanchez and Ericsson, {Paula Gonzalez} and Kuba, {Maria G.} and Sanders, {Melinda E.} and Mu, {Xinmeng J.} and {Van Allen}, {Eliezer M.} and Nikhil Wagle and Mayer, {Ingrid A.} and Vandana Abramson and Henry G{\'o}mez and Monica Rizzo and Weiyi Toy and Sarat Chandarlapaty and Mayer, {Erica L.} and Jason Christiansen and Danielle Murphy and Kerry Fitzgerald and Kai Wang and Ross, {Jeffrey S.} and Miller, {Vincent A.} and Stephens, {Phillip J.} and Roman Yelensky and Levi Garraway and Yu Shyr and Ingrid Meszoely and Balko, {Justin M.} and Arteaga, {Carlos L.}",
year = "2017",
month = "8",
day = "9",
doi = "10.1126/scitranslmed.aai7993",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "402",

}

TY - JOUR

T1 - Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

AU - Giltnane, Jennifer M.

AU - Hutchinson, Katherine E.

AU - Stricker, Thomas P.

AU - Formisano, Luigi

AU - Young, Christian D.

AU - Estrada, Monica V.

AU - Nixon, Mellissa J.

AU - Du, Liping

AU - Sanchez, Violeta

AU - Ericsson, Paula Gonzalez

AU - Kuba, Maria G.

AU - Sanders, Melinda E.

AU - Mu, Xinmeng J.

AU - Van Allen, Eliezer M.

AU - Wagle, Nikhil

AU - Mayer, Ingrid A.

AU - Abramson, Vandana

AU - Gómez, Henry

AU - Rizzo, Monica

AU - Toy, Weiyi

AU - Chandarlapaty, Sarat

AU - Mayer, Erica L.

AU - Christiansen, Jason

AU - Murphy, Danielle

AU - Fitzgerald, Kerry

AU - Wang, Kai

AU - Ross, Jeffrey S.

AU - Miller, Vincent A.

AU - Stephens, Phillip J.

AU - Yelensky, Roman

AU - Garraway, Levi

AU - Shyr, Yu

AU - Meszoely, Ingrid

AU - Balko, Justin M.

AU - Arteaga, Carlos L.

PY - 2017/8/9

Y1 - 2017/8/9

N2 - Inhibition of proliferation in estrogen receptor-positive (ER+) breast cancers after short-term antiestrogen therapy correlates with long-term patient outcome. We profiled 155 ER+/human epidermal growth factor receptor 2-negative (HER2) early breast cancers from 143 patients treated with the aromatase inhibitor letrozole for 10 to 21 days before surgery. Twenty-one percent of tumors remained highly proliferative, suggesting that these tumors harbor alterations associated with intrinsic endocrine therapy resistance. Whole-exome sequencing revealed a correlation between 8p11-12 and 11q13 gene amplifications, including FGFR1 and CCND1, respectively, and high Ki67. We corroborated these findings in a separate cohort of serial pretreatment, postneoadjuvant chemotherapy, and recurrent ER+ tumors. Combined inhibition of FGFR1 and CDK4/6 reversed antiestrogen resistance in ER+ FGFR1/CCND1 coamplified CAMA1 breast cancer cells. RNA sequencing of letrozole-treated tumors revealed the existence of intrachromosomal ESR1 fusion transcripts and increased expression of gene signatures indicative of enhanced E2F-mediated transcription and cell cycle processes in cancers with high Ki67. These data suggest that short-term preoperative estrogen deprivation followed by genomic profiling can be used to identify druggable alterations that may cause intrinsic endocrine therapy resistance.

AB - Inhibition of proliferation in estrogen receptor-positive (ER+) breast cancers after short-term antiestrogen therapy correlates with long-term patient outcome. We profiled 155 ER+/human epidermal growth factor receptor 2-negative (HER2) early breast cancers from 143 patients treated with the aromatase inhibitor letrozole for 10 to 21 days before surgery. Twenty-one percent of tumors remained highly proliferative, suggesting that these tumors harbor alterations associated with intrinsic endocrine therapy resistance. Whole-exome sequencing revealed a correlation between 8p11-12 and 11q13 gene amplifications, including FGFR1 and CCND1, respectively, and high Ki67. We corroborated these findings in a separate cohort of serial pretreatment, postneoadjuvant chemotherapy, and recurrent ER+ tumors. Combined inhibition of FGFR1 and CDK4/6 reversed antiestrogen resistance in ER+ FGFR1/CCND1 coamplified CAMA1 breast cancer cells. RNA sequencing of letrozole-treated tumors revealed the existence of intrachromosomal ESR1 fusion transcripts and increased expression of gene signatures indicative of enhanced E2F-mediated transcription and cell cycle processes in cancers with high Ki67. These data suggest that short-term preoperative estrogen deprivation followed by genomic profiling can be used to identify druggable alterations that may cause intrinsic endocrine therapy resistance.

UR - http://www.scopus.com/inward/record.url?scp=85027421288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027421288&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aai7993

DO - 10.1126/scitranslmed.aai7993

M3 - Article

C2 - 28794284

AN - SCOPUS:85027421288

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 402

M1 - aai7993

ER -